{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:22:08Z","timestamp":1794558128821,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-55316-5","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T10:22:08Z","timestamp":1736158928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["MAT2A inhibitor AG-270\/S095033 in patients with advanced malignancies: a phase I trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Mrinal","family":"Gounder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-1314","authenticated-orcid":false,"given":"Melissa","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Heist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-4095","authenticated-orcid":false,"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-1857","authenticated-orcid":false,"given":"Sophie","family":"Postel-Vinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5019-0186","authenticated-orcid":false,"given":"Frederick H.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-7842","authenticated-orcid":false,"given":"Elena","family":"Garralda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7868-6231","authenticated-orcid":false,"given":"Gerburg","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Almon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah","family":"Nabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Aguado-Fraile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Narayanaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Sadou-Dubourgnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Askoxylakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"55316_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4161\/cbt.4.1.1380","volume":"4","author":"SR Hustinx","year":"2005","unstructured":"Hustinx, S. R. et al. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. Cancer Biol. Ther. 4, 83\u201386 (2005).","journal-title":"Cancer Biol. Ther."},{"key":"55316_CR2","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1038\/sj.onc.1202205","volume":"17","author":"M Schmid","year":"1998","unstructured":"Schmid, M. et al. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). Oncogene 17, 2669\u20132675 (1998).","journal-title":"Oncogene"},{"key":"55316_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/gcc.20867","volume":"50","author":"J Kim","year":"2011","unstructured":"Kim, J. et al. Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma. Genes Chromosomes Cancer 50, 421\u2013433 (2011).","journal-title":"Genes Chromosomes Cancer"},{"key":"55316_CR4","first-page":"326","volume":"13","author":"AL De Souza","year":"2023","unstructured":"De Souza, A. L. et al. Clinical features of patients with MTAP-deleted bladder cancer. Am. J. Cancer Res. 13, 326\u2013339 (2023).","journal-title":"Am. J. Cancer Res."},{"key":"55316_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/(SICI)1098-2264(199805)22:1<72::AID-GCC10>3.0.CO;2-K","volume":"22","author":"MH Dreyling","year":"1998","unstructured":"Dreyling, M. H., Roulston, D., Bohlander, S. K., Vardiman, J. & Olopade, O. I. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin\u2019s lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer 22, 72\u201378 (1998).","journal-title":"Genes Chromosomes Cancer"},{"key":"55316_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24240-3","volume":"12","author":"Y Barekatain","year":"2021","unstructured":"Barekatain, Y. et al. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine. Nat. Commun. 12, 4228 (2021).","journal-title":"Nat. Commun."},{"key":"55316_CR7","unstructured":"Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548\u20131565 (2018)."},{"key":"55316_CR8","unstructured":"ICGC\/TCGA. Pan-cancer analysis of whole genomes consortium. Pan-cancer analysis of whole genomes. Nature 578, 82\u201393 (2020)."},{"key":"55316_CR9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905 (2010).","journal-title":"Nature"},{"key":"55316_CR10","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1158\/0008-5472.CAN-18-1010","volume":"79","author":"LJ Hansen","year":"2019","unstructured":"Hansen, L. J. et al. MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation. Cancer Res. 79, 3383\u20133394 (2019).","journal-title":"Cancer Res."},{"key":"55316_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.ejso.2014.04.017","volume":"40","author":"C-Y Su","year":"2014","unstructured":"Su, C.-Y. et al. MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients. Eur. J. Surg. Oncol. 40, 1143\u20131150 (2014).","journal-title":"Eur. J. Surg. Oncol."},{"key":"55316_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0165-4608(95)00157-3","volume":"86","author":"H Zhang","year":"1996","unstructured":"Zhang, H., Chen, Z. H. & Savarese, T. M. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. Cancer Genet. Cytogenet. 86, 22\u201328 (1996).","journal-title":"Cancer Genet. Cytogenet."},{"key":"55316_CR13","doi-asserted-by":"crossref","unstructured":"Vrugt, B. et al. Deletions of CDKN2A and MTAP detected by copy-number variation array are associated with loss of p16 and MTAP protein in pleural mesothelioma. Cancers 15, 4978 (2023).","DOI":"10.3390\/cancers15204978"},{"key":"55316_CR14","doi-asserted-by":"crossref","unstructured":"Chapel, D. B., Dubuc, A. M., Hornick, J. L. & Sholl, L. M. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma. Histopathology 78, 1032\u20131042 (2021).","DOI":"10.1111\/his.14324"},{"key":"55316_CR15","doi-asserted-by":"crossref","unstructured":"Huang, H. Y. et al. Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors. Clin. Cancer Res. 15, 6963\u20136972 (2009).","DOI":"10.1158\/1078-0432.CCR-09-1511"},{"key":"55316_CR16","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aad5214","volume":"351","author":"GV Kryukov","year":"2016","unstructured":"Kryukov, G. V. et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351, 1214\u20131218 (2016).","journal-title":"Science"},{"key":"55316_CR17","doi-asserted-by":"crossref","unstructured":"Mavrakis, K. J. et al. Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5. Science 351, 1208\u20131213 (2016).","DOI":"10.1126\/science.aad5944"},{"key":"55316_CR18","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","volume":"15","author":"K Marjon","year":"2016","unstructured":"Marjon, K. et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis. Cell Rep. 15, 574\u2013587 (2016).","journal-title":"Cell Rep."},{"key":"55316_CR19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ccell.2019.07.003","volume":"36","author":"JY Fong","year":"2019","unstructured":"Fong, J. Y. et al. Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation. Cancer Cell 36, 194\u2013209.e9 (2019).","journal-title":"Cancer Cell"},{"key":"55316_CR20","doi-asserted-by":"publisher","first-page":"105492","DOI":"10.1016\/j.jbc.2023.105492","volume":"300","author":"GT Bedard","year":"2024","unstructured":"Bedard, G. T. et al. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition. J. Biol. Chem. 300, 105492 (2024).","journal-title":"J. Biol. Chem."},{"key":"55316_CR21","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1021\/acs.jmedchem.0c01895","volume":"64","author":"Z Konteatis","year":"2021","unstructured":"Konteatis, Z. et al. Discovery of AG-270, a first-in-class oral MAT2A inhibitor for the treatment of tumors with homozygous MTAP deletion. J. Med. Chem. 64, 4430\u20134449 (2021).","journal-title":"J. Med. Chem."},{"key":"55316_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","volume":"39","author":"P Kalev","year":"2021","unstructured":"Kalev, P. et al. MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. Cancer Cell 39, 209\u2013224.e11 (2021).","journal-title":"Cancer Cell"},{"key":"55316_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"55316_CR24","doi-asserted-by":"publisher","first-page":"1264785","DOI":"10.3389\/fonc.2023.1264785","volume":"13","author":"C Bray","year":"2023","unstructured":"Bray, C., Balcells, C., McNeish, I. A. & Keun, H. C. The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality. Front. Oncol. 13, 1264785 (2023).","journal-title":"Front. Oncol."},{"key":"55316_CR25","doi-asserted-by":"publisher","first-page":"S766","DOI":"10.1016\/j.annonc.2022.07.620","volume":"33","author":"ML Johnson","year":"2022","unstructured":"Johnson, M. L. et al. 492TiP a phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion. Ann. Oncol. 33, S766\u2013S767 (2022).","journal-title":"Ann. Oncol."},{"key":"55316_CR26","doi-asserted-by":"publisher","unstructured":"Ramani, K. & Lu, S. C. Methionine adenosyltransferases in liver health and diseases. Liver Res. 1. https:\/\/doi.org\/10.1016\/j.livres.2017.07.002 (2017).","DOI":"10.1016\/j.livres.2017.07.002"},{"key":"55316_CR27","doi-asserted-by":"crossref","unstructured":"Lu, S. C. et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc. Natl. Acad. Sci. USA 98, 5560\u20135565 (2001).","DOI":"10.1073\/pnas.091016398"},{"key":"55316_CR28","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/1538-7445.AM2021-1278","volume":"81","author":"MM Fischer","year":"2021","unstructured":"Fischer, M. M. et al. Abstract 1278: MAT2A inhibitor, IDE397, displays broad anti-tumor activity across a panel of MTAP-deleted patient-derived xenografts. Cancer Res. 81, 1278\u20131278 (2021).","journal-title":"Cancer Res."},{"key":"55316_CR29","unstructured":"IDEAYA. IDEAYA Biosciences reports IDE397 interim phase 1 clinical data. https:\/\/media.ideayabio.com\/2022-03-15-IDEAYA-Biosciences-Reports-IDE397-Interim-Phase-1-Clinical-Data (2023)."},{"key":"55316_CR30","unstructured":"IDEAYA. IDEAYA announces top-line phase 2 results at ESMO 2023 of Darovasertib and Crizotinib combo in MUM, and clinical efficacy updates for neoadjuvant UM, GNAQ\/11 cutaneous melanoma, and synthetic lethality pipeline. https:\/\/media.ideayabio.com\/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline (2023)."},{"key":"55316_CR31","unstructured":"IDEAYA. IDEAYA announces positive interim phase 2 monotherapy expansion data for IDE397 a potential first-in-class MAT2A inhibitor in MTAP-deletion urothelial and lung cancer. https:\/\/ir.ideayabio.com\/2024-07-08-IDEAYA-Announces-Positive-Interim-Phase-2-Monotherapy-Expansion-Data-for-IDE397-a-Potential-First-in-Class-MAT2A-Inhibitor-in-MTAP-Deletion-Urothelial-and-Lung-Cancer (2023)."},{"key":"55316_CR32","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1158\/1538-7445.AM2023-1644","volume":"83","author":"MM Fischer","year":"2023","unstructured":"Fischer, M. M. et al. Abstract 1644: dual inhibition of MAT2A and PRMT5 delivers synergistic anti-tumor responses in preclinical models of MTAP-deleted cancer. Cancer Res. 83, 1644\u20131644 (2023).","journal-title":"Cancer Res."},{"key":"55316_CR33","doi-asserted-by":"publisher","first-page":"20538","DOI":"10.1073\/pnas.1106946108","volume":"108","author":"L Sun","year":"2011","unstructured":"Sun, L. et al. Structural insights into protein arginine symmetric dimethylation by PRMT5. Proc. Natl. Acad. Sci. USA 108, 20538\u201320543 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"55316_CR34","doi-asserted-by":"publisher","first-page":"17960","DOI":"10.1073\/pnas.1209814109","volume":"109","author":"S Antonysamy","year":"2012","unstructured":"Antonysamy, S. et al. Crystal structure of the human PRMT5:MEP50 complex. Proc. Natl. Acad. Sci. USA 109, 17960\u201317965 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"55316_CR35","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","volume":"13","author":"LD Engstrom","year":"2023","unstructured":"Engstrom, L. D. et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov. 13, 2412\u20132431 (2023).","journal-title":"Cancer Discov."},{"key":"55316_CR36","doi-asserted-by":"crossref","unstructured":"AMG 193 effective in multiple tumor types. Cancer Discov. 13, 2492 (2023).","DOI":"10.1158\/2159-8290.CD-NB2023-0079"},{"key":"55316_CR37","doi-asserted-by":"crossref","unstructured":"Rodon, J. et al. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Ann. Oncol. 35, 1138\u20131147 (2024).","DOI":"10.1016\/j.annonc.2024.08.2339"},{"key":"55316_CR38","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.exphem.2015.08.013","volume":"43","author":"Z Abdul-Sater","year":"2015","unstructured":"Abdul-Sater, Z. et al. FANCA safeguards interphase and mitosis during hematopoiesis in vivo. Exp. Hematol. 43, 1031\u20131046.e12 (2015).","journal-title":"Exp. Hematol."},{"key":"55316_CR39","doi-asserted-by":"publisher","first-page":"e1184802","DOI":"10.1080\/2162402X.2016.1184802","volume":"5","author":"FC Henrich","year":"2016","unstructured":"Henrich, F. C. et al. Suppressive effects of tumor cell-derived 5\u2032-deoxy-5\u2032-methylthioadenosine on human T cells. Oncoimmunology 5, e1184802 (2016).","journal-title":"Oncoimmunology"},{"key":"55316_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07697-0","volume":"12","author":"LJ Hansen","year":"2022","unstructured":"Hansen, L. J. et al. MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization. Sci. Rep. 12, 4183 (2022).","journal-title":"Sci. Rep."},{"key":"55316_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21804-1","volume":"12","author":"MH Hung","year":"2021","unstructured":"Hung, M. H. et al. Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nat. Commun. 12, 1455 (2021).","journal-title":"Nat. Commun."},{"key":"55316_CR42","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.ccell.2023.09.005","volume":"41","author":"D Gjuka","year":"2023","unstructured":"Gjuka, D. et al. Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance. Cancer Cell 41, 1774\u20131787.e9 (2023).","journal-title":"Cancer Cell"},{"key":"55316_CR43","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1158\/1078-0432.CCR-21-0575","volume":"27","author":"E Adib","year":"2021","unstructured":"Adib, E. et al. CDKN2A alterations and response to immunotherapy in solid tumors. Clin. Cancer Res. 27, 4025\u20134035 (2021).","journal-title":"Clin. Cancer Res."},{"key":"55316_CR44","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1200\/JCO.2022.40.16_suppl.2622","volume":"40","author":"E Adib","year":"2022","unstructured":"Adib, E. et al. Dual CDKN2A\/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors. J. Clin. Oncol. 40, 2622 (2022).","journal-title":"J. Clin. Oncol."},{"key":"55316_CR45","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1073\/pnas.81.9.2665","volume":"81","author":"CJ Carrera","year":"1984","unstructured":"Carrera, C. J., Eddy, R. L., Shows, T. B. & Carson, D. A. Assignment of the gene for methylthioadenosine phosphorylase to human chromosome 9 by mouse-human somatic cell hybridization. Proc. Natl. Acad. Sci. USA 81, 2665\u20132668 (1984).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"55316_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25894-9","volume":"12","author":"G Han","year":"2021","unstructured":"Han, G. et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat. Commun. 12, 5606 (2021).","journal-title":"Nat. Commun."},{"key":"55316_CR47","first-page":"2108","volume":"9","author":"PB Illei","year":"2003","unstructured":"Illei, P. B., Rusch, V. W., Zakowski, M. F. & Ladanyi, M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin. Cancer Res. 9, 2108\u20132113 (2003).","journal-title":"Clin. Cancer Res."},{"key":"55316_CR48","unstructured":"National Cancer Institute. The Cancer Genome Atlas: TCGA Research Network."},{"key":"55316_CR49","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"55316_CR50","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"55316_CR51","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/sim.3230","volume":"27","author":"B Neuenschwander","year":"2008","unstructured":"Neuenschwander, B., Branson, M. & Gsponer, T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat. Med. 27, 2420\u20132439 (2008).","journal-title":"Stat. Med."},{"key":"55316_CR52","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9","volume":"17","author":"J Babb","year":"1998","unstructured":"Babb, J., Rogatko, A. & Zacks, S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat. Med. 17, 1103\u20131120 (1998).","journal-title":"Stat. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55316-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55316-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55316-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T11:02:26Z","timestamp":1736161346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55316-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55316"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55316-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.H., M.R., M.H., R.N., A.S.-D., M.C., and V.A. are employed by Servier. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"423"}}